Moleculin Biotech Inc Stock Prediction and Forecast [MBRX]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 03 Dec 2025, 03:58 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Moleculin Biotech Inc Stock Prediction and Forecast [MBRX]](https://i.ytimg.com/vi/VKa8aKj3lcA/hqdefault.jpg)
AI-generated source summary
The video provides a technical analysis of MBRX stock, traded on NASDAQ. As of December 2, 2025, the analysis assigns a strong sell candidate rating with a score of negative 5, and its current value is at $6.63. The stock is currently at the lower end of a very wide and declining trend. If it breaks below the trend floor of $6.62, then the decrease will be pronounced. The prediction for the trend over the next 3 months varies from -2.95% to +90.31%. Over the next 12 months, the price is projected to drop by 64.65%, where it may vary from complete loss to +17.68%. An initial pivot bottom buy signal was indicated. However, negative signals have developed. Moving averages reveal a negative forecast. The next price is anticipated on December 3 at $6.66 when it is likely to open higher by 3 cents. Accumulation/distribution trading data indicates no support, and the analysis shows weekly volatility is at 7.62% or very high risk.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.